MeiraGTx Holdings plc Operating Lease, Expense
MeiraGTx Holdings plc (MGTX) reported Operating Lease, Expense of $800.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-13
- MeiraGTx Holdings plc operating lease, expense for the quarter ending 2026-06-30 was $800.00K, a 38.46% decline year-over-year.
- MeiraGTx Holdings plc operating lease, expense for the quarter ending 2026-03-31 was $1.20M, a 7.69% decline year-over-year.
- MeiraGTx Holdings plc operating lease, expense for the quarter ending 2025-12-31 was $1.10M, a 15.38% decline year-over-year.
- MeiraGTx Holdings plc operating lease, expense for the quarter ending 2025-09-30 was $1.30M, a 7.14% decline year-over-year.
- MeiraGTx Holdings plc operating lease, expense for fiscal 2025 was $4.80M, a 14.29% decline from fiscal 2024.
- MeiraGTx Holdings plc operating lease, expense for fiscal 2024 was $5.60M, a 1.82% increase from fiscal 2023.
- MeiraGTx Holdings plc operating lease, expense for fiscal 2023 was $5.50M, a 3.77% increase from fiscal 2022.
- MeiraGTx Holdings plc operating lease, expense for fiscal 2022 was $5.30M, a 6.00% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 6 month as first filed | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $800.00K 10-Q · filed 2026-08-13 | $2.10M 10-Q · filed 2026-08-13 | $3.10M derived: sum of 3 quarters · filed 2026-08-13 | $4.40M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-14 | $2.30M derived: sum of 2 quarters · filed 2026-05-14 | $3.60M derived: sum of 3 quarters · filed 2026-05-14 | $4.90M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.40M derived: sum of 2 quarters · filed 2026-03-30 | $3.70M derived: sum of 3 quarters · filed 2026-08-13 | $4.80M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $1.30M 10-Q · filed 2025-11-13 | $2.60M derived: sum of 2 quarters · filed 2026-08-13 | $3.70M 10-Q · filed 2025-11-13 | $5.20M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.30M 10-Q · filed 2026-08-13 | $2.50M 10-Q · filed 2026-08-13 | $3.90M derived: sum of 3 quarters · filed 2026-08-13 | $5.30M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $1.30M 10-Q · filed 2026-05-14 | $2.60M derived: sum of 2 quarters · filed 2026-05-14 | $4.00M derived: sum of 3 quarters · filed 2026-05-14 | $5.40M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.70M derived: sum of 2 quarters · filed 2026-03-30 | $4.10M derived: sum of 3 quarters · filed 2026-03-30 | $5.60M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $1.40M 10-Q · filed 2025-11-13 | $2.80M derived: sum of 2 quarters · filed 2025-11-13 | $4.30M 10-Q · filed 2025-11-13 | $5.60M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $1.40M 10-Q · filed 2025-08-14 | $2.90M 10-Q · filed 2025-08-14 | $4.20M derived: sum of 3 quarters · filed 2025-08-14 | $5.60M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $1.40M 10-Q · filed 2025-05-13 | $2.80M derived: sum of 2 quarters · filed 2025-05-13 | $4.20M derived: sum of 3 quarters · filed 2025-05-13 | $5.60M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.80M derived: sum of 2 quarters · filed 2025-03-13 | $4.20M derived: sum of 3 quarters · filed 2025-03-13 | $5.50M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $1.40M 10-Q · filed 2024-11-13 | $2.80M derived: sum of 2 quarters · filed 2024-11-13 | $4.10M 10-Q · filed 2024-11-13 | $5.50M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $1.40M 10-Q · filed 2024-08-12 | $2.70M 10-Q · filed 2024-08-12 | $4.10M derived: sum of 3 quarters · filed 2024-08-12 | $5.40M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $1.40M 10-Q · filed 2024-05-09 | $2.70M derived: sum of 2 quarters · filed 2024-05-09 | $4.00M derived: sum of 3 quarters · filed 2024-05-09 | $5.30M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $2.60M derived: sum of 2 quarters · filed 2024-03-15 | $3.90M derived: sum of 3 quarters · filed 2024-03-15 | $5.30M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $1.30M 10-Q · filed 2023-11-14 | $2.60M derived: sum of 2 quarters · filed 2023-11-14 | $4.00M 10-Q · filed 2023-11-14 | $5.20M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $1.30M 10-Q · filed 2023-08-10 | $2.60M 10-Q · filed 2023-08-10 | $3.90M derived: sum of 3 quarters · filed 2023-08-10 | $5.20M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $1.30M 10-Q · filed 2023-05-11 | $2.60M derived: sum of 2 quarters · filed 2023-05-11 | $3.90M derived: sum of 3 quarters · filed 2023-05-11 | $5.20M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $2.60M derived: sum of 2 quarters · filed 2023-03-14 | $3.90M derived: sum of 3 quarters · filed 2023-03-14 | $5.00M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $1.30M 10-Q · filed 2022-11-10 | $2.60M derived: sum of 2 quarters · filed 2022-11-10 | $3.70M 10-Q · filed 2022-11-10 | $4.50M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $1.30M 10-Q · filed 2022-08-11 | $2.40M 10-Q · filed 2022-08-11 | $3.20M derived: sum of 3 quarters · filed 2022-08-11 | $4.00M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $1.10M 10-Q · filed 2022-05-12 | $1.90M derived: sum of 2 quarters · filed 2022-05-12 | $2.70M derived: sum of 3 quarters · filed 2022-05-12 | $3.60M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.60M derived: sum of 2 quarters · filed 2022-03-10 | $2.50M derived: sum of 3 quarters · filed 2022-03-10 | $3.30M 10-K · filed 2022-03-10 | $3.34M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $800.00K 10-Q · filed 2021-11-10 | $829.81K 10-Q · filed 2020-11-05 | $1.70M derived: sum of 2 quarters · filed 2021-11-10 | $2.50M 10-Q · filed 2021-11-10 | $2.49M 10-Q · filed 2020-11-05 | $3.56M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $900.00K 10-Q · filed 2021-08-11 | $901.04K 10-Q · filed 2020-08-06 | $1.70M 10-Q · filed 2021-08-11 | $1.66M 10-Q · filed 2020-08-06 | $2.76M derived: sum of 3 quarters · filed 2021-08-11 | $3.48M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $800.00K 10-Q · filed 2021-05-11 | $759.37K 10-Q · filed 2020-05-07 | $1.86M derived: sum of 2 quarters · filed 2021-05-11 | $2.58M derived: sum of 3 quarters · filed 2021-05-11 | $2.68M derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $1.78M derived: sum of 2 quarters · filed 2021-03-11 | $1.88M derived: sum of 3 quarters · filed 2021-03-11 | $1.78M 10-K · filed 2021-03-11 | $487.56K 10-K · filed 2020-03-11 | |||
| 2019-09-30 | $718.58K 10-Q · filed 2020-11-05 | $820.74K derived: sum of 2 quarters · filed 2020-11-05 | $718.58K 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $102.15K 10-Q · filed 2020-08-06 | $189.41K 10-Q · filed 2020-08-06 | ||||||
| 2019-03-31 | $89.66K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |